
    
      The primary objectives are to assess safety of Rift Valley Fever (RVF) Vaccine, Inactivated
      (TSI-GSD 200) and to assess immunogenicity of Rift Valley Fever (RVF) Vaccine, Inactivated
      (TSI-GSD 200). The secondary objective is to assess incidence of RVF infection in vaccinated
      personnel
    
  